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Abstract
AIM: To investigate the safety and effectiveness of 
endoscopic therapy with a paclitaxel-eluting balloon 
(PEB) for biliary anastomotic stricture (AS) after liver 
transplantation (LT).
METHODS: This prospective pilot study enrolled 13 
consecutive eligible patients treated for symptomatic 
AS after LT at the University Hospital of Münster be-
tween January 2011 and March 2014. The patients 
were treated by endoscopic therapy with a PEB and 
followed up every 8 wk by endoscopic retrograde chol-
angiopancreatography (ERCP). In cases of re-stenosis, 
further balloon dilation with a PEB was performed. 
Follow-up was continued until 24 mo after the last in-
tervention.
RESULTS: Initial technical feasibility, defined as suc-
cessful balloon dilation with a PEB during the initial 
ERCP procedure, was achieved in 100% of cases. 
Long-term clinical success (LTCS), defined as no need 
for further endoscopic intervention for at least 24 mo, 
was achieved in 12 of the 13 patients (92.3%). The 
mean number of endoscopic interventions required to 
achieve LTCS was only 1.7 ± 1.1. Treatment failure, 
defined as the need for definitive alternative treat-
ment, occurred in only one patient, who developed 
recurrent stenosis with increasing bile duct dilatation 
that required stent placement.
CONCLUSION: Endoscopic therapy with a PEB is very 
effective for the treatment of AS after LT, and seems to 
significantly shorten the overall duration of endoscopic 
treatment by reducing the number of interventions 
needed to achieve LTCS.
Key words: Liver transplantation; Anastomotic stric-
ture; Endoscopic therapy; Endoscopic retrograde chol-
angiopancreatography; Balloon dilation; Paclitaxel-
eluting balloon
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Core tip: Biliary anastomotic stricture is common after 
liver transplantation and can significantly impair both 
organ and patient survival. Endoscopic treatment of 
an anastomotic stricture usually requires many in-
terventions before long-term resolution is achieved. 
This study investigated the safety and efficacy of an 
innovative approach using endoscopic therapy with a 
paclitaxel-eluting balloon for the treatment of biliary 
anastomotic stricture after liver transplantation. Our 
data are very promising and show excellent long-term 
results. Furthermore, use of a paclitaxel-eluting bal-
loon seems to reduce the number of endoscopic inter-
ventions needed to achieve sustained resolution of the 
stricture.
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INTRODUCTION
Biliary complications are common after liver transplantation 
(LT) because the vascular supply to the biliary tract is 
easily injured, and such complications are a major cause 
of  morbidity and graft failure. Biliary complications are 
reported to occur in 10%-25% of  LT recipients, and may 
include stricture, leakage, and formation of  biliary stones, 
casts, and sludge[1-3]. Biliary stricture is one of  the most 
commonly reported complications after LT and can be 
divided into two types: anastomotic stricture (AS) and 
non-anastomotic stricture. This categorization helps to 
predict the response to treatment, with AS responding 
more favorably to endoscopic intervention than non-
anastomotic stricture[3,4].
AS is the most frequent biliary complication after 
LT, accounting for 8%-20% of  all complications. 
Endoscopic retrograde cholangiopancreatography (ERCP) 
is considered to be the gold standard for diagnosis and 
treatment of  biliary complications after LT. Current 
standard endoscopic interventions for AS include 
balloon dilation and stent placement. Most patients 
require repeated endoscopic procedures for 12 to 24 mo, 
during which they undergo an average of  5-6 endoscopic 
interventions. The reported success rate of  balloon 
dilation alone is about 40%, and the reported overall 
long-term success rate after endoscopic interventions 
is 75%-80%. However, AS recurrence after successful 
endoscopic treatment has been reported in up to 30% of  
cases[5-7].
In recent years, fully covered self-expandable metal 
stents have been used to treat biliary strictures after LT 
when standard endoscopic treatment failed. Treatment 
with such stents has a success rate of  nearly 80%, but 
also has a high complication rate of  up to 47%, mainly 
due to stent migration, stent occlusion, and de novo 
stricture formation[1,8,9].
New treatment modalities are needed to reduce 
procedure-related morbidity and the overall duration 
of  endoscopic treatment, as well as to improve long-
term results. The short-term outcome data of  this study 
published in 2012 were very promising[10]. The aim of  
this pilot study was to evaluate the long-term safety and 
effectiveness of  endoscopic therapy with a paclitaxel-
eluting balloon (PEB) for AS after LT.
MATERIALS AND METHODS
This prospective study was conducted between January 
2011 and March 2014 in the Department of  Transplant 
Medicine, University Hospital of  Münster. Thirteen 
consecutive eligible patients were enrolled between 
January 2011 and September 2011, and follow-up was 
performed until March 2014.
All patients gave written informed consent, and the 
study was conducted in accordance with the guidelines 
of  the Declaration of  Helsinki (2004 revision). The 
study protocol was finalized after consultation with the 
local institutional review board.
All patients with newly diagnosed AS after LT who 
had undergone end-to-end choledochocholedochostomy 
were eligible for inclusion in the study. Patients who had 
undergone choledochojejunostomy were excluded.
AS was defined as a narrowing of  the bile duct, 
predominantly at the anastomotic site, with markedly 
reduced passage of  contrast material observed on 
fluoroscopy during ERCP. ERCP was performed if  
there were clinical, biochemical, or histological signs of  
cholestasis, or dilated bile ducts on imaging examinations 
(ultrasonography, computed tomography, or magnetic 
resonance tomography). Four of  the 13 patients 
(30.8%) had dilated bile ducts on non-invasive imaging 
examinations.
Endoscopic procedure
ERCP was performed using a therapeutic duodenoscope 
(TJF-180V, Olympus Corp., Tokyo, Japan) under 
conscious sedation (midazolam and propofol, with or 
without opiates) and antibiotic prophylaxis (ciprofloxacin 
750 mg orally 2 h before and 6 h after the procedure). 
The bile duct was accessed using a sphincterotome (Tri-
Tome, TRI 20, Cook Medical, Winston-Salem, NC, 
United States) and a wire (0.035 inches, THSF-35-480, 
Cook Medical) to guide cannulation. Cholangiography 
was performed to assess the biliary anastomosis. The 
guidewire was then advanced through the stricture.
If  AS was diagnosed, endoscopic treatment was 
performed, comprising sphincterotomy followed by 
dilation with a PEB (DIOR paclitaxel coated coronary 
balloon dilatation catheter, paclitaxel 3 μg/mm2; Eurocor, 
Bonn, Germany). The PEB was coated with a 1:1 
mixture of  paclitaxel and shellac that prevented release 
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Table 1  Laboratory parameters
of  paclitaxel in the working channel of  the endoscope. 
Contact of  the hydrophilic shellac mixture with a body 
fluid such as bile opens the structure to allow pressure-
induced release of  paclitaxel on the inflated balloon. The 
PEB was inflated at the anastomotic site to a pressure of  
up to 12 bar, and left in place for 30 s (Figure 1). After 
the initial balloon dilation, ERCP was performed every 
8 wk to re-evaluate the stricture. If  cholangiography 
showed a patent anastomosis, no further endoscopic 
treatment was performed. If  the stricture persisted, 
further dilation with a PEB was performed. Follow-up 
was continued until 24 mo after the last intervention.
Definitions and statistical analysis
The main outcome parameter of  this prospective study 
was long-term clinical success (LTCS), defined as a 
period of  at least 24 mo without the need for further 
endoscopic intervention, confirmed by the absence of  
stricture recurrence on follow-up ERCP examinations, 
laboratory test results indicating cholestasis, or clinical 
signs of  jaundice or cholangitis. The secondary outcome 
parameters were initial technical feasibility, sustained 
clinical success (SCS), and treatment failure.
Initial technical feasibility was defined as successful 
advancement of  a guidewire through the AS followed 
by balloon dilation during the initial ERCP procedure. 
SCS was defined as a period of  at least 6 mo with no 
need for further endoscopic intervention, confirmed by 
the absence of  stricture recurrence on follow-up ERCP 
examinations. Treatment failure was defined as the need 
for definitive alternative treatment at any time during the 
follow-up period, such as stent placement, percutaneous 
transhepatic drainage, or surgical intervention.
Descriptive statistical analyses were performed. Data 
are presented as the mean ± SD. All statistical analyses 
were performed using SPSS version 20 for Windows.
RESULTS
A total of  13 patients (2 women, 11 men, mean age 
50.4 ± 13.8 years) who were referred for endoscopic 
treatment of  newly diagnosed AS after LT were included 
in the study. The mean time from LT to the initial ERCP 
procedure was 9.4 ± 3.2 mo. The indications for LT were 
alcoholic cirrhosis (n = 5), hepatitis B virus infection (n 
= 2), hepatitis C virus infection (n = 2), hepatocellular 
carcinoma (n = 3), and primary biliary cirrhosis (n = 1).
The initial technical feasibility rate was 100%, and 
no intra-procedural complications were recorded. Liver 
enzyme levels and cholestasis parameters decreased 
after the initial procedure in all patients (Table 1). Two 
patients developed acute cholangitis within 3 d after the 
last intervention, which resolved after antibiotic therapy 
with imipenem. There were no cases of  post-ERCP 
pancreatitis. The mean follow-up period was 30.3 ± 3.3 
mo. SCS was achieved in 12 of  13 patients (92.3%): after 
one dilation in nine patients (69%), after two dilations 
in one patient, and after three dilations in two patients. 
Despite initial technical feasibility, the remaining patient 
developed AS recurrence with increasing bile duct 
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Before intervention 7 d after intervention 24 mo after last intervention
Bilirubin 6.8 ± 4.1   2.2 ± 1.3   1.4 ± 0.6
(reference value < 1.2 mg/dL)
GPT 149.1 ± 120.1   51.5 ± 21.3 35.1 ± 3.9
(reference value 10-35 U/L)
GGT 614.5 ± 330.0 107.1 ± 62.8   37.7 ± 10.1
(reference value < 39 U/L)
A B C
Figure 1  Endoscopic therapy for a biliary anastomotic stricture. A: Anastomotic stricture after liver transplantation (arrow); B: The inflated balloon has a waist at 
the narrowest part of the stricture (arrow); C: Resolution of the stricture after balloon dilation.
GPT: Glutamic-pyruvic transaminase; GGT: Gamma-glutamyl transferase.
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dilatation proximal to the stenosis after three dilations 
with a PEB, and eventually underwent conventional stent 
placement. This case was considered to be a treatment 
failure. AS recurrence after SCS was observed in 2/12 
patients (16.6%). The time interval between the initial 
balloon dilation and AS recurrence was 8.89 ± 0.63 mo. 
In each of  these two patients, one additional dilation was 
needed to achieve LTCS. LTCS was eventually achieved 
in all 12 patients (92.3%) who achieved SCS, after a 
mean of  1.7 ± 1.1 balloon dilations.
After successful endoscopic treatment of  the 
stenosis, the bilirubin and liver enzyme levels decreased 
over time in all patients (Table 1).
DISCUSSION
Biliary tract complications are common after LT, 
and present a therapeutic challenge for endoscopists. 
Endoscopic intervention is currently the gold standard 
treatment for AS after LT[1-3], but the optimal treatment 
strategy for this complication is still unclear. Repeated 
endoscopic interventions over a prolonged treatment 
period of  up to 24 mo are usually needed to achieve 
SCS[4-7]. Moreover, there are few data available regarding 
the rate of  AS recurrence after SCS[4]. When endoscopic 
therapy is unsuccessful, surgical treatment is indicated[2,11].
The limitations of  the currently available treatment 
options clearly demonstrate the need for development 
of  new interventions. Considering the fibroproliferative 
aspect of  AS, a therapeutic approach that combines 
balloon dilation with application of  an antiproliferative 
agent directly to the site of  the stenosis seems logical. 
The mitotic inhibitor paclitaxel has antiproliferative 
effects as well as antifibrotic effects via inhibition of  
transforming growth factor-beta/Smad activity[12,13]. Use 
of  PEBs has previously been shown to be clinically safe 
and effective for the treatment of  coronary and femoro-
popliteal arterial stenoses[14,15].
This is the first study to investigate endoscopic treatment 
with a PEB for AS after LT. SCS was achieved in 92.3% 
of  cases, and was achieved after only one balloon dilation 
in 69% of  cases. AS recurrence after SCS occurred in 
16.6% of  patients, which is much less frequent than the 
previously reported recurrence rate of  about 30%[5-7]. 
All cases of  AS recurrence were successfully treated by 
repeat balloon dilation. LTCS was achieved in 92.3% of  
cases, after 1.7 ± 1.1 balloon dilations. This is a notable 
achievement in comparison with previous reports that 
five or six interventions were generally required to achieve 
sustained resolution of  AS[1-3,5].
Successful endoscopic treatment was associated with 
significantly decreased levels of  bilirubin and liver enzymes 
(Table 1).
In this pilot study, endoscopic therapy with a PEB 
achieved a high rate of  LTCS and a low rate of  AS 
recurrence after SCS, indicating very promising outcomes 
for our treatment approach for AS after LT. Use of  
a PEB seems to reduce the number of  interventional 
procedures required to achieve LTCS, thereby shortening 
the overall duration of  endoscopic treatment. A reduced 
number of  endoscopic interventions may also result in a 
decreased overall complication rate. Larger randomized 
clinical trials are needed to confirm our findings.
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